Adjuvant Docetaxel Does Not Help Biochemical DFS in High-risk PCa
In prostate cancer, adjuvant docetaxel without hormone therapy did not improve biochemical disease-free survival after radical prostatectomy.
Diagnosis & Disease Information
TRUS-biopsy Inferior for Prostate Cancer Detection
Transrectal ultrasound-guided (TRUS) prostate biopsy poorly detects and rules out clinically significant prostate cancer.
Enzalutamide-Abiraterone-Leuprolide Ineffective for Localized PCa
Adding enzalutamide to abiraterone acetate and leuprolide acetate does not appear to be effective for the treatment of localized high-risk prostate cancer.
Cytoreductive RC Aids Survival of Metastatic Bladder Cancer Patients
Patients who underwent debulking had significantly longer overall survival compared with those who did not (median 15.7 vs 10 months).
Patients on Psychiatric Meds Report More Severe OAB Symptoms
These same patients, however, had less intense detrusor overactivity, urodynamic evaluation revealed.
Survival Advantage Confirmed for Nephrectomy in mRCC
About 25% of patients who present with metastatic renal cancer will undergo nephrectomy after diagnosis.
Bariatric Surgery May Ease LUTS in Obese Men
Study documents significant improvements in frequency, urgency, and nocturia.
Cytoreductive Nephrectomy Benefits Select mRCC Patients Taking TT
Among patients treated with targeted therapy, overall survival was 17.1 months for CN recipients vs 7.7 months for those without CN.
Neoadjuvant Chemo Rarely Used in Upper Tract Urothelial Cancer
Therapy used in less than 5% of cases, even in those with higher clinical stage.
PPIs Linked With Higher Rate of Post-RP Complications
Prostate cancer patients taking proton pump inhibitors also had pathologically higher stage disease.
- Loading...
Loading...
Next post in AUA 2016 Prostate Cancer
Loading... 
Loading...